2.4. KRAS Inhibitors AMG510 and BI-3406 Inhibit KRAS Activation and Signaling through the RAS/MAPK Pathway in KRAS Mutant Pancreatic Cancer Cells. This evidence concerns the gene KRAS and familial pancreatic carcinoma.